To assess the bioquivalence of carbamazepine ( CBZ ) controlled release formulation A ( Tegretol CR , local ) vs formulation B ( Tegretol CR , Basel ) and confirm their controlled release characteristics by comparing with conventional formulation ( Tegretol ) .
